Arcutis Biotherapeutics Current Valuation vs. Cash Per Share

ARQT Stock  USD 12.25  0.52  4.07%   
Based on Arcutis Biotherapeutics' profitability indicators, Arcutis Biotherapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Arcutis Biotherapeutics' ability to earn profits and add value for shareholders. Price To Sales Ratio is likely to drop to 3.57 in 2024. Days Sales Outstanding is likely to drop to 150.13 in 2024. At this time, Arcutis Biotherapeutics' Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Change To Netincome is likely to gain to about 76.1 M in 2024, despite the fact that Operating Income is likely to grow to (229 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.690.9163
Way Down
Very volatile
For Arcutis Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Arcutis Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Arcutis Biotherapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Arcutis Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Arcutis Biotherapeutics over time as well as its relative position and ranking within its peers.
  

Arcutis Biotherapeutics' Revenue Breakdown by Earning Segment

Check out Trending Equities.
For more information on how to buy Arcutis Stock please use our How to Invest in Arcutis Biotherapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcutis Biotherapeutics. If investors know Arcutis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcutis Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.67)
Revenue Per Share
1.228
Quarterly Revenue Growth
0.174
Return On Assets
(0.31)
Return On Equity
(1.92)
The market value of Arcutis Biotherapeutics is measured differently than its book value, which is the value of Arcutis that is recorded on the company's balance sheet. Investors also form their own opinion of Arcutis Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcutis Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcutis Biotherapeutics' market value can be influenced by many factors that don't directly affect Arcutis Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcutis Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcutis Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcutis Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Arcutis Biotherapeutics Cash Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Arcutis Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Arcutis Biotherapeutics value to that of its competitors to determine the firm's financial worth.
Arcutis Biotherapeutics is rated third in current valuation category among its peers. It is rated fourth in cash per share category among its peers . The ratio of Current Valuation to Cash Per Share for Arcutis Biotherapeutics is about  250,873,204 . At this time, Arcutis Biotherapeutics' Cash Per Share is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcutis Biotherapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Arcutis Current Valuation vs. Competition

Arcutis Biotherapeutics is rated third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 7.37 Billion. Arcutis Biotherapeutics retains roughly 1.37 Billion in current valuation claiming about 19% of equities under Health Care industry.

Arcutis Cash Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Arcutis Biotherapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
1.37 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Arcutis Biotherapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
5.47 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Arcutis Cash Per Share Comparison

Arcutis Biotherapeutics is currently under evaluation in cash per share category among its peers.

Arcutis Biotherapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Arcutis Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Arcutis Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Arcutis Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Arcutis Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive IncomeK4.2 K
Operating Income-241.1 M-229 M
Net Loss-267.9 M-254.5 M
Income Before Tax-259 M-246.1 M
Total Other Income Expense Net-17.9 M-17 M
Net Loss-280.3 M-266.3 M
Net Loss-262.1 M-249 M
Income Tax Expense3.1 MM
Net Interest Income-28.9 M-27.4 M
Non Operating Income Net Other155.7 K147.9 K
Change To Netincome72.4 M76.1 M
Net Loss(3.78)(3.97)
Income Quality 0.94  0.68 
Net Income Per E B T 1.01  0.81 

Arcutis Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Arcutis Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Arcutis Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Arcutis Biotherapeutics' important profitability drivers and their relationship over time.

Use Arcutis Biotherapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arcutis Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arcutis Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Arcutis Biotherapeutics Pair Trading

Arcutis Biotherapeutics Pair Trading Analysis

The ability to find closely correlated positions to Arcutis Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arcutis Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arcutis Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arcutis Biotherapeutics to buy it.
The correlation of Arcutis Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arcutis Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arcutis Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arcutis Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Arcutis Biotherapeutics position

In addition to having Arcutis Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Construction Materials Thematic Idea Now

Construction Materials
Construction Materials Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Arcutis Stock Analysis

When running Arcutis Biotherapeutics' price analysis, check to measure Arcutis Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcutis Biotherapeutics is operating at the current time. Most of Arcutis Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Arcutis Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcutis Biotherapeutics' price. Additionally, you may evaluate how the addition of Arcutis Biotherapeutics to your portfolios can decrease your overall portfolio volatility.